An exploratory clinical study on the safety of combination therapy with effector cell therapy and immune checkpoint inhibitors.

Trial Profile

An exploratory clinical study on the safety of combination therapy with effector cell therapy and immune checkpoint inhibitors.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2017

At a glance

  • Drugs Immunotherapies (Primary) ; Nivolumab (Primary)
  • Indications Cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Oct 2017 Status changed from not yet recruiting to recruiting.
    • 24 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top